Opus Genetics, Inc. (IRD) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 9.86M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $9.86M | (m) | (m) |
| 2026-03-31 | (m) | $11.98M | (m) | (m) |
| 2025-12-31 | (m) | $14.20M | (m) | (m) |
| 2025-09-30 | (m) | $14.63M | (m) | (m) |
| 2025-06-30 | (m) | $15.42M | (m) | (m) |
| 2025-03-31 | (m) | $13.65M | (m) | (m) |
| 2024-12-31 | (m) | $10.99M | (m) | (m) |
| 2024-09-30 | (m) | $8.38M | (m) | (m) |
| 2024-06-30 | (m) | $16.45M | (m) | (m) |
| 2024-03-31 | (m) | $19.01M | (m) | (m) |
| 2023-12-31 | (m) | $19.05M | (m) | (m) |
| 2023-09-30 | (m) | $57.21M | (m) | (m) |
| 2023-06-30 | (m) | $45.27M | (m) | (m) |
| 2023-03-31 | (m) | $41.60M | (m) | (m) |
| 2022-12-31 | (m) | $39.85M | (m) | (m) |
| 2022-09-30 | (m) | $0.00 | (m) | (m) |
| 2022-06-30 | (m) | $489.00K | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $589.00K | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $0.00 | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $0.00 | (m) | (m) |
| 2013-12-31 | (m) | $0.00 | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $0.00 | (m) | (m) |
| 2012-12-31 | (m) | $0.00 | (m) | (m) |
| 2012-09-30 | (m) | $0.00 | (m) | (m) |
| 2012-06-30 | (m) | $0.00 | (m) | (m) |
| 2012-03-31 | (m) | $0.00 | (m) | (m) |
| 2011-12-31 | (m) | $0.00 | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $0.00 | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |